#glp-1
3 pieces tagged glp-1.
- Where the line isRetatrutide is investigational: what that status meansRetatrutide (LY3437943) is Eli Lilly's single-peptide agonist of the GIP, GLP-1 and glucagon receptors, with no FDA-approved product as of September 2026. What 'investigational' means, and why a research vial is not the trial drug.
- Where the line isWhat ended for compounded semaglutide and tirzepatide, and whenCompounded tirzepatide and semaglutide were allowed only while the approved products were in shortage. The shortages and grace periods ended in 2024 and 2025. What is still open, and why a research vial is no substitute.
- The moleculesCagrilintide is an amylin analogue, not a GLP-1Cagrilintide descends from the pancreatic hormone amylin, not from GLP-1. What the molecule is, how it was engineered, why it is paired with semaglutide in trials, and its status as of September 21, 2026.
Nothing here is medical advice. Everything on this site is supplied for laboratory research use only.